Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Eccojc/1040"'
2
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naive SB5 Observational Cohorts
Autor: Laura Kirckpatrick, Caitlin S Rees, Lauranne A A P Derikx, Claire O'Hare, Charlie W. Lees, Nikolas Plevris, Philip Jenkinson, S Siakavellas, Nathan Constantine-Cooke, Laura Lucaciu, Gareth-Rhys Jones, Heather W Dolby, Lynne M Merchant, Ian D. Arnott, Colin L. Noble, Shanna Su, Mathew Lyons
Publikováno v: Journal of Crohn's and Colitis, 15, 2011-2021
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 15, 12, pp. 2011-2021
Background and Aims Multiple adalimumab [ADA] biosimilars are now approved for use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We aimed to investigate long-term outcomes of the ADA biosimilar SB5 in IBD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c18e73aade15417255084528433aa1
https://hdl.handle.net/2066/244226
Zobrazit plný text záznamu
3
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
Autor: Leonardo Salese, Rajiv Mundayat, Chinyu Su, Gary S. Friedman, Nervin Lawendy, Kevin L. Winthrop, Gary Chan, Walter Reinisch, Chudy I. Nduaka, Edward V. Loftus, Andrew John Thorpe, Daniel C. Baumgart
Publikováno v: Journal of Crohn's & Colitis
Background and Aims Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes. Methods Three cohorts were analysed: Induction [
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7744bb9ab6fd07bfa4bec39ecc7c0753
https://doi.org/10.1093/ecco-jcc/jjaa233
Zobrazit plný text záznamu
4
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
Autor: Raj Bhandari, M. Teresa Pulido-Rios, David T Beattie, Reuben Sana, Brihad Abhyankar, Jonathan A. Leighton, Jacky Woo, Richard Graham, Eva Situ, Ravi Ganeshappa, Erik Sandvik, Melanie A. Kleinschek, Whitney Krey, David L. Boyle, Deanna D Nguyen, Julián Panés, William J. Sandborn, Patrick Brassil
Publikováno v: Journal of Crohn's & Colitis
Journal of Crohn's & colitis, vol 14, iss 9
Background and Aims Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities. We describe preclinical to clinical translation of TD-1473—an oral gut-selective pan-JAK inhibitor—from in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5f63ccc3b54b28cf78acb55ba9f1eb
https://doi.org/10.1093/ecco-jcc/jjaa049
Zobrazit plný text záznamu
5
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
Autor: Marc Ferrante, Arthur Kaser, Geert R. D'Haens, Wan-Ju Lee, Julián Panés, Xiaomei Liao, Olivier Dewit, Brian G. Feagan, Filip Baert, Jasmina Kalabic, W. Rachel Duan, Kori Wallace, Yinuo Pang, Dawn Gustafson, Edouard Louis
Publikováno v: Journal of Crohn's & colitis, 15(12), 2001-2010. Elsevier
Journal of Crohn's & colitis, Vol. 15, no.12, p. 2001-2010 (2021)
Journal of Crohn's & Colitis
Background and Aims Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. This open-label extension investigated the long-term safety
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e418780af15ef3e836bc2ac0db175f7
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-risankizumab-treatment-in-patients-with-crohns-disease(2efdb272-1af3-47e5-a541-ad43af36fa8f).html
Zobrazit plný text záznamu
6
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
Autor: Julián Panés, Xiang Guo, Severine Vermeire, Leonardo Salese, Wenjin Wang, Chinyu Su, Jean-Frederic Colombel, Edward V. Loftus, Irene Modesto, Nervin Lawendy, Marla Dubinsky
Publikováno v: Journal of Crohn's & Colitis
Background and Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-treatment following treatment interruption in patients with ulcerat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2ec5d5d57a7424fa6a70ded49187ae
https://lirias.kuleuven.be/handle/20.500.12942/690909
Zobrazit plný text záznamu
7
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
Autor: Severine Vermeire, Irene Modesto, Nervin Lawendy, Nicole Kulisek, David T. Rubin, Haiying Zhang, Chinyu Su, Taku Kobayashi, Sean Gardiner, William J. Sandborn, Wenjin Wang, Julián Panés
Publikováno v: Journal of Crohn's & Colitis
Background and Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomised, parallel-group trial evaluating eff
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b60c8aaed65fa695372e3572f04078a
https://lirias.kuleuven.be/handle/123456789/670865
Zobrazit plný text záznamu
8
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
Autor: Silvio Danese, Yuri Sanchez Gonzalez, Edward V. Loftus, Julián Panés, Subrata Ghosh, Wangang Xie, Wen Zhou, Edouard Louis, Ryan Clark
Publikováno v: Journal of Crohn's & Colitis
Background and Aims Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not commonly assessed in clinical trials. We evaluated how these symptoms may improve with upadacitinib treatment and correlate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a11e38b36cef515732863d35db35e4
https://pubmed.ncbi.nlm.nih.gov/34107013
Zobrazit plný text záznamu
9
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
Autor: Stanley A. Cohen, Dan Turner, Anne M. Griffiths, Omoniyi J. Adedokun, Douglas A Jacobstein, Christopher D. O'Brien, Jeffrey S. Hyams, Lakshmi Padgett, Joel R. Rosh, Natalie A. Terry
Publikováno v: Journal of Crohn's & Colitis
Background and Aims The objective was to evaluate the pharmacokinetics, safety/tolerability, and efficacy of ustekinumab in children with moderately to severely active Crohn’s disease. Methods In this Phase 1, multicentre, 16-week, double-blind, in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e352d3e278f718281078763c8de7f01
https://pubmed.ncbi.nlm.nih.gov/34037715
Zobrazit plný text záznamu
10
Body, Soul, and Hypnotherapy
Autor: Shomron Ben-Horin, Ehud Mekori-Domachevsky
Publikováno v: Journal of Crohn's & Colitis
Background and Aims Many inflammatory bowel disease [IBD] patients in remission have persisting symptoms, compatible with irritable bowel syndrome [IBS-type symptoms]. We aimed to compare the effectiveness of gut-directed hypnotherapy vs standard med
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16b58245856a80d5b26d0a795efafdb9
https://pubmed.ncbi.nlm.nih.gov/33245332
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje